Bio-Techne (TECH) Q3 2026 Earnings Transcript

Bio-Techne reported Q3 revenue of $311.4 million, down 2% organically and on a reported basis, while adjusted EPS fell to $0.53 from $0.56 and adjusted operating margin compressed 70 bps to 34.2%. Offsetting the headline decline, operating cash flow was strong at $86.7 million, gross margin improved sequentially to 70.4%, and management reiterated fourth-quarter organic growth of approximately flat with about 100 bps of margin expansion exiting the year. The company cited a 3% cell-therapy timing headwind and weak emerging biotech spending, but highlighted double-digit large-pharma growth, record COMET backlog, China growth for a fourth straight quarter, and continued M&A priority.

Analysis

TECH is no longer a simple top-line recovery story; it is a timing-resolution story with multiple near-term distortions that should unwind into fiscal 2027. The key second-order effect is that the company is carrying two different lag structures at once: biotech funding has improved, but customer spending is still following the historical 2-3 quarter delay, while the cell-therapy/Fast Track mix issue suppresses current-period reagent demand but also front-loads future commercial upside. That means the market likely underestimates how much of the current flat guide is self-inflicted/transitory versus structural.

The cleaner read is that core demand is bifurcating by workflow quality. Large pharma, spatial biology, and proteomic instrumentation are the early-cycle indicators, and those businesses are already doing the work of de-risking the recovery; the weak spot is early-stage biotech, which is exactly where budget mix has shifted away. If that mix shift persists, TECH’s recovery will be slower than peers who are more levered to later-stage translational spend, but if biotech broadens beyond late-stage programs, TECH should see disproportionate operating leverage because the fixed-cost structure is already showing through in margins and cash flow.

The contrarian setup is that consensus may be overly focused on the revenue miss and underappreciating the quality of the backlog/signals underneath spatial biology, China, and the cell-therapy funnel. The highest-risk item is not demand collapse; it is that early-stage biotech spending fails to normalize by the first half of fiscal 2027, which would turn the current 'timing' story into a longer duration growth gap. Conversely, a modest pickup in biotech orders could create a sharp multiple re-rate because the stock is already being priced against a flat near-term base while margin expansion and M&A optionality remain intact.

Key Decisions for Investors

• Initiate a tactical long TECH into the next 4-8 weeks on weakness, targeting the Q4 setup; thesis is that flat guide plus easing cell-therapy and OEM timing headwinds creates asymmetrical upside if biotech orders start to inflect.
• Pair trade: long TECH / short a more biotech-early-cycle reagent peer with higher exposure to discovery spending over the next 2 quarters; TECH should outperform if the recovery remains led by large pharma, spatial, and instruments rather than broad discovery.
• Buy TECH Jan-2027 calls or call spreads; the trade is for fiscal 2027 mid-single-digit growth to become credible as timing headwinds roll off, with margin expansion providing additional torque.
• Trim or hedge if early-stage biotech spending does not improve by the June/September 2026 quarters; that would invalidate the '2-3 quarter lag' thesis and likely cap multiple expansion.
• Add on confirmation: use China/spatial biology order strength as the trigger, not reported revenue, because those are the earliest indicators that customer budgets are re-opening.